zithromax i.v.
pfizer pfe pharmaceuticals israel ltd - azithromycin as dihydrate - powder for solution for infusion - azithromycin as dihydrate 500 mg/vial - azithromycin - azithromycin - treatment of infections caused by susceptible strains of the designated microorganisms in the following conditions: community-acquired pneumonia and pelvic inflammatory disease.
clindamycin injections
rafa laboratories ltd - clindamycin as phosphate - solution for injection - clindamycin as phosphate 150 mg/ml - clindamycin - clindamycin - the treatment of infections caused by susceptible anaerobic bacteria.
dalacin c 150 mgml
pfizer pfe pharmaceuticals israel ltd - clindamycin phosphate - solution for injection - clindamycin phosphate 150 mg/ml - clindamycin - clindamycin - for the treatment of infections caused by susceptible anaerobic bacteria.
herceptin 440 mg i.v
roche pharmaceuticals (israel) ltd - trastuzumab - solution for infusion - trastuzumab 440 mg/ml - trastuzumab - trastuzumab - herceptin is indicated for the treatment of patients with metastatic breast cancer who have tumours that overexpress her2: 1. as a single agent for the treatment of those patients who have received one or more chemotherapy regiments for their metastatic disease. 2. in combination with paclitaxel or docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease. 3. herceptin in combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive metastatic breast cancer. early breast cancer (ebc) :herceptin is indicated to treat patients with her2-positive early breast cancer following surgery and chemotherapy (neoadjuvant or adjuvant) either alone or in combination with chemotherapy excluding anthracyclines. herceptin should only be used in patients whose tumors have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay.her2 metastatic gastric cancer (mgc)herceptin in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-esophageal junction who have not received prior anti-cancer treatment for their metastatic disease.herceptin should only be used in patients with metastatic gastric cancer whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory fish+ result, or ihc 3+, as determined by an accurate and validated assay
eptifibatide strides 0.75 mg/ml solution for infusion
strides arcolab international limited - eptifibatide - solution for infusion - 0.75 mg/ml
eptifibatide strides 2 mg/ml solution for injection
strides arcolab international limited - eptifibatide - solution for injection - 2 mg/ml
fungizone 50 mg powder for sterile concentrate
bristol-myers squibb pharmaceuticals uc - amphotericin - powder for solution for infusion - 50 milligram(s) - antibiotics; amphotericin b
geroquel 300 mg film-coated tablets
mcdermott laboratories ltd t/a gerard laboratories - quetiapine fumarate - film-coated tablet - 300 milligram(s) - diazepines, oxazepines, thiazepines and oxepines; quetiapine
doribax™ powder for injection 500mg
celltrion healthcare singapore private limited - doripenem monohydrate - injection, powder, lyophilized, for suspension - 500 mg - doripenem monohydrate 500 mg
erbitux 5mgml
merck pte. ltd. - cetuximab, chimeric antibody - infusion, solution - 5mg/ml - cetuximab, chimeric antibody 5mg/ml